These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 36240540

  • 1. A battery of tandem mass spectrometry assays with stable isotope-dilution for the quantification of 15 anti-tuberculosis drugs and two metabolites in patients with susceptible-, multidrug-resistant- and extensively drug-resistant tuberculosis.
    Mercier T, Desfontaine V, Cruchon S, Da Silva Pereira Clara JA, Briki M, Mazza-Stalder J, Kajkus A, Burger R, Suttels V, Buclin T, Opota O, Koehler N, Sanchez Carballo PM, Lange C, André P, Decosterd LA, Choong E.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Nov 15; 1211():123456. PubMed ID: 36240540
    [Abstract] [Full Text] [Related]

  • 2. High clustering rate and genotypic drug-susceptibility screening for the newly recommended anti-tuberculosis drugs among global extensively drug-resistant Mycobacterium tuberculosis isolates.
    Trisakul K, Nonghanphithak D, Chaiyachat P, Kaewprasert O, Sakmongkoljit K, Reechaipichitkul W, Chaiprasert A, Blair D, Clark TG, Faksri K.
    Emerg Microbes Infect; 2022 Dec 15; 11(1):1857-1866. PubMed ID: 35792049
    [Abstract] [Full Text] [Related]

  • 3. Diagnostic accuracy of a liquid chromatography-tandem mass spectrometry assay in small hair samples for rifampin-resistant tuberculosis drug concentrations in a routine care setting.
    Metcalfe J, Bacchetti P, Esmail A, Reckers A, Aguilar D, Wen A, Huo S, Muyindike WR, Hahn JA, Dheda K, Gandhi M, Gerona R.
    BMC Infect Dis; 2021 Jan 22; 21(1):99. PubMed ID: 33482745
    [Abstract] [Full Text] [Related]

  • 4. A Single-Run HPLC-MS Multiplex Assay for Therapeutic Drug Monitoring of Relevant First- and Second-Line Antibiotics in the Treatment of Drug-Resistant Tuberculosis.
    Köhler N, Karaköse H, Grobbel HP, Hillemann D, Andres S, König C, Kalsdorf B, Brehm TT, Böttcher L, Friesen I, Hoffmann H, Strelec D, Schaub D, Peloquin CA, Schmiedel S, Decosterd LA, Choong E, Wicha SG, Aarnoutse RE, Lange C, Sánchez Carballo PM.
    Pharmaceutics; 2023 Oct 27; 15(11):. PubMed ID: 38004523
    [Abstract] [Full Text] [Related]

  • 5. Validation and clinical application of a multiplex high performance liquid chromatography - tandem mass spectrometry assay for the monitoring of plasma concentrations of 12 antibiotics in patients with severe bacterial infections.
    Decosterd LA, Mercier T, Ternon B, Cruchon S, Guignard N, Lahrichi S, Pesse B, Rochat B, Burger R, Lamoth F, Pagani JL, Eggimann P, Csajka C, Choong E, Buclin T, Widmer N, André P, Marchetti O.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Nov 10; 1157():122160. PubMed ID: 32891946
    [Abstract] [Full Text] [Related]

  • 6. Assessing potential drug-drug interactions between clofazimine and other frequently used agents to treat drug-resistant tuberculosis.
    Kengo A, Nabeemeeah F, Denti P, Sabet R, Okyere-Manu G, Abraham P, Weisner L, Mosala MH, Tshabalala S, Scholefield J, Resendiz-Galvan JE, Martinson NA, Variava E.
    Antimicrob Agents Chemother; 2024 May 02; 68(5):e0158323. PubMed ID: 38597667
    [Abstract] [Full Text] [Related]

  • 7. Simultaneous quantification of isoniazid, rifampicin, ethambutol and pyrazinamide by liquid chromatography/tandem mass spectrometry.
    Prahl JB, Lundqvist M, Bahl JM, Johansen IS, Andersen ÅB, Frimodt-Møller N, Cohen AS.
    APMIS; 2016 Nov 02; 124(11):1004-1015. PubMed ID: 27546025
    [Abstract] [Full Text] [Related]

  • 8. First report of whole-genome analysis of an extensively drug-resistant Mycobacterium tuberculosis clinical isolate with bedaquiline, linezolid and clofazimine resistance from Uganda.
    Kabahita JM, Kabugo J, Kakooza F, Adam I, Guido O, Byabajungu H, Namutebi J, Namaganda MM, Lutaaya P, Otim J, Kakembo FE, Kanyerezi S, Nabisubi P, Sserwadda I, Kasule GW, Nakato H, Musisi K, Oola D, Joloba ML, Mboowa G.
    Antimicrob Resist Infect Control; 2022 May 12; 11(1):68. PubMed ID: 35550202
    [Abstract] [Full Text] [Related]

  • 9. Simple and accurate quantitative analysis of 20 anti-tuberculosis drugs in human plasma using liquid chromatography-electrospray ionization-tandem mass spectrometry.
    Kim HJ, Seo KA, Kim HM, Jeong ES, Ghim JL, Lee SH, Lee YM, Kim DH, Shin JG.
    J Pharm Biomed Anal; 2015 Jan 12; 102():9-16. PubMed ID: 25218029
    [Abstract] [Full Text] [Related]

  • 10. Rapid and highly sensitive quantification of the anti-tuberculosis agents isoniazid, ethambutol, pyrazinamide, rifampicin and rifabutin in human plasma by UPLC-MS/MS.
    Wu L, Ye Z, Liu H, Guo H, Lin J, Zheng L, Chu N, Liu X.
    J Pharm Biomed Anal; 2020 Feb 20; 180():113076. PubMed ID: 31896523
    [Abstract] [Full Text] [Related]

  • 11. Development and validation of a simple LC-MS/MS method for simultaneous determination of moxifloxacin, levofloxacin, prothionamide, pyrazinamide and ethambutol in human plasma.
    Zheng X, Jongedijk EM, Hu Y, Kuhlin J, Zheng R, Niward K, Paues J, Xu B, Davies Forsman L, Schön T, Bruchfeld J, Alffenaar JC.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Nov 20; 1158():122397. PubMed ID: 33091676
    [Abstract] [Full Text] [Related]

  • 12. Validation and application of a quantitative LC-MS/MS assay for the analysis of first-line anti-tuberculosis drugs, rifabutin and their metabolites in human breast milk.
    Zuma P, Joubert A, van der Merwe M, Norman J, Waitt C, Court R, Loveday M, Castel S, Wiesner L.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Nov 15; 1211():123489. PubMed ID: 36215877
    [Abstract] [Full Text] [Related]

  • 13. Different macrophage polarization between drug-susceptible and multidrug-resistant pulmonary tuberculosis.
    Cho HJ, Lim YJ, Kim J, Koh WJ, Song CH, Kang MW.
    BMC Infect Dis; 2020 Jan 29; 20(1):81. PubMed ID: 31996142
    [Abstract] [Full Text] [Related]

  • 14. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M, Mok J, Kim DK, Shim TS, Koh WJ, Jeon D, Lee T, Lee SH, Kim JS, Park JS, Lee JY, Kim SY, Lee JH, Jo KW, Jhun BW, Kang YA, Ahn JH, Kim CK, Shin S, Song T, Shin SJ, Kim YR, Ahn H, Hahn S, Won HJ, Jang JY, Cho SN, Yim JJ.
    Trials; 2019 Jan 16; 20(1):57. PubMed ID: 30651149
    [Abstract] [Full Text] [Related]

  • 15. Mitigating treatment failure of pulmonary pre-extensively drug-resistant tuberculosis: The role of new and repurposed drugs.
    Huang YW, Yu MC, Lin CB, Lee JJ, Lin CJ, Chien ST, Lee CH, Chiang CY.
    J Microbiol Immunol Infect; 2024 Aug 16; 57(4):617-628. PubMed ID: 38705821
    [Abstract] [Full Text] [Related]

  • 16. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
    Dawson R, Diacon AH, Everitt D, van Niekerk C, Donald PR, Burger DA, Schall R, Spigelman M, Conradie A, Eisenach K, Venter A, Ive P, Page-Shipp L, Variava E, Reither K, Ntinginya NE, Pym A, von Groote-Bidlingmaier F, Mendel CM.
    Lancet; 2015 May 02; 385(9979):1738-1747. PubMed ID: 25795076
    [Abstract] [Full Text] [Related]

  • 17. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK, Kim JH, Kang H, Cho JS, Smego RA.
    Int J Infect Dis; 2009 Mar 02; 13(2):170-5. PubMed ID: 18768342
    [Abstract] [Full Text] [Related]

  • 18. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
    Zhang SJ, Yang Y, Sun WW, Zhang ZS, Xiao HP, Li YP, Zhang ZM, Fan L.
    BMC Infect Dis; 2022 Aug 29; 22(1):715. PubMed ID: 36038829
    [Abstract] [Full Text] [Related]

  • 19. Standardization and validation of a novel UPLC-MS/MS method to quantify first line anti-tuberculosis drugs in plasma and dried blood spots.
    Herrera-Pérez IG, Rodríguez-Báez AS, Ortiz-Álvarez A, Velarde-Salcedo R, Arriaga-García FJ, Rodríguez-Pinal CJ, Romano-Moreno S, Milán-Segovia RDC, Medellín-Garibay SE.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Aug 01; 1228():123801. PubMed ID: 37453389
    [Abstract] [Full Text] [Related]

  • 20. Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial.
    Patil SB, Tamirat M, Khazhidinov K, Ardizzoni E, Atger M, Austin A, Baudin E, Bekhit M, Bektasov S, Berikova E, Bonnet M, Caboclo R, Chaudhry M, Chavan V, Cloez S, Coit J, Coutisson S, Dakenova Z, De Jong BC, Delifer C, Demaisons S, Do JM, Dos Santos Tozzi D, Ducher V, Ferlazzo G, Gouillou M, Khan U, Kunda M, Lachenal N, LaHood AN, Lecca L, Mazmanian M, McIlleron H, Moreau M, Moschioni M, Nahid P, Osso E, Oyewusi L, Panda S, Pâquet A, Thuong Huu P, Pichon L, Rich ML, Rupasinghe P, Salahuddin N, Sanchez Garavito E, Seung KJ, Velásquez GE, Vallet M, Varaine F, Yuya-Septoh FJ, Mitnick CD, Guglielmetti L.
    Trials; 2023 Nov 30; 24(1):773. PubMed ID: 38037119
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.